Results 11 to 20 of about 98,224 (178)

Docetaxel-related interstitial pneumonitis

Therapeutics and Clinical Risk Management, 2015
Chung-Jen Wang, Hou-Tai Chang, Cheng-Yu Chang Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Abstract: Docetaxel (Taxotere®) is an agent that is indicated for the treatment of ...
Wang CJ, Chang HT, Chang CY
doaj   +1 more source

Docetaxel suppressed cell proliferation through Smad3/HIF-1α-mediated glycolysis in prostate cancer cells

Cell Communication and Signaling, 2022
Background Tumor glycolysis is a critical event for tumor progression. Docetaxel is widely used as a first-line drug for chemotherapy and shown to have a survival advantage.
Junming Peng, Zhijun He, Yeqing Yuan, Jing Xie, Yu Zhou, Baochun Guo, Jinan Guo   +6 more
doaj   +1 more source

Nanocrystal-Loaded Micelles for the Enhanced In Vivo Circulation of Docetaxel

Molecules, 2021
Prolonging in vivo circulation has proved to be an efficient route for enhancing the therapeutic effect of rapidly metabolized drugs. In this study, we aimed to construct a nanocrystal-loaded micelles delivery system to enhance the blood circulation of ...
Meng Cheng, Qiaoming Liu, Tiantian Gan, Yuanying Fang, Pengfei Yue, Yongbing Sun, Yi Jin, Jianfang Feng, Liangxing Tu   +8 more
doaj   +1 more source

The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment

Cell & Bioscience, 2023
Background Prostate cancer is a leading cause of cancer-related deaths among men worldwide. Docetaxel chemotherapy has proven effective in improving overall survival in patients with castration-resistant prostate cancer (CRPC), but drug resistance ...
Bisheng Cheng, Lingfeng Li, Yongxin Wu, Tianlong Luo, Chen Tang, Qiong Wang, Qianghua Zhou, Jilin Wu, Yiming Lai, Dingjun Zhu, Tao Du, Hai Huang   +11 more
doaj   +1 more source

Study of the Effect of Linoleic Acid on the Expression Level of MicroRNA-106b and MicroRNA-20a and their Related Target MHC Class I Chain-related Protein A in Docetaxel-treated Gastric Cancer Cells [PDF]

Middle East Journal of Cancer, 2021
Background: MicroRNAs are involved in response to therapeutic agents and have the ability to regulate the expression level of the targets associated with cancer growth and progression.
Najibeh Shekari, Tohid Kazemi, Maedeh Moradi, Elham Eghbali, Bita Sepehri, Vahid Khaze Shahgoli, Masoud Shirmohamadi   +6 more
doaj   +1 more source

Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer

BMC Cancer, 2021
Background Overcoming drug resistance is critical for increasing the survival rate of prostate cancer (PCa). Docetaxel is the first cytotoxic chemotherapeutical approved for treatment of PCa.
Patricia M. Schnepp, Aqila Ahmed, June Escara-Wilke, Jinlu Dai, Greg Shelley, Jill Keller, Atsushi Mizokami, Evan T. Keller   +7 more
doaj   +1 more source

High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer [PDF]

, 2005
Background: Docetaxel is one of the most effective antitumor agents currently available for the treatment of metastatic breast cancer (MBC). This phase II multicenter study prospectively analyzed the efficacy and toxicity of docetaxel given on a weekly ...
Abenhardt, Wolfgang, Leinung, S., V. Heinemann, Stemmler, J., W. Mair, Jackisch, C., O. Brudler, G. Deutsch, Stamp, J., Dorn, B., J. Stemmler, Brudler, O., Stauch, M., M. Malekmohammadi, Papke, J., M. Stauch, Deutsch, G., Vehling-Kaiser, U., S. Leinung, B. Dorn, Heinemann, Volker, C. Jackisch, U. Vehling-Kaiser, Mair, W., Kentenich, C., J. Papke, C. Kentenich, Malekmohammadi, M., W. Abenhardt, J. Stamp   +29 more
core   +1 more source

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer [PDF]

, 2010
Purpose: Previous phase II studies have indicated a greatly reduced hematotoxicity of docetaxel-based regimens administered on weekly schedules. The present trial was initiated to randomly compare the toxicity and efficacy of weekly docetaxel versus its ...
Abenhardt, Wolfgang, Rauthe, Gerhard, Marion Kiechle, Stemmler, Hans-Joachim, Heinemann, Volker, Harald Sommer, Artmann, Almut, Sommer, Harald, Isolde Gröll de Rivera, Hans-Gerd Meerpohl, de Rivera, Isolde Groell, Meerpohl, Hans-Gerd, Nadia Harbeck, Gerhard Rauthe, Harbeck, Nadia, Volker Heinemann, Kiechle, Marion, Kaiser, Ursula Vehling, Ursula Vehling Kaiser, Wolfgang Abenhardt, Almut Artmann, Hans-Joachim Stemmler, Stemmler, Hans-Joachim;Harbeck, Nadia;Gröll de Rivera, Isolde;Vehling Kaiser, Ursula;Rauthe, Gerhard;Abenhardt, Wolfgang;Artmann, Almut;Sommer, Harald;Meerpohl, Hans-Gerd;Kiechle, Marion;Heinemann, Volker, Stemmler, HJ;Harbeck, N;Gröll de Rivera, I;Vehling Kaiser, U;Rauthe, G;Abenhardt, W;Artmann, A;Sommer, H;Meerpohl, HG;Kiechle, M;Heinemann, V   +23 more
core   +1 more source

Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castration-resistant Prostate Cancer Patients

Zhongliu Fangzhi Yanjiu, 2019
Objective To assess the efficacy of docetaxel rechallenge on castration-resistant prostate cancer (mCRPC) patients and to analyze prognostic factors. Methods We retrospectively reviewed the medical history of 120 mCRPC patients treated with the first ...
DUAN Liqun, ZHANG Qu, LIU Sanhe, DENG Kangli, WEI Shaozhong   +4 more
doaj   +1 more source

Mesenchymal stem cells desensitize castration-resistant prostate cancer to docetaxel chemotherapy via inducing TGF-β1-mediated cell autophagy

Cell & Bioscience, 2021
Background Mesenchymal stem cells (MSCs) have been proved to drive castration resistant prostate cancer (CRPC). In this study, we aim to investigate the contribution of MSCs to the development of docetaxel resistance in CRPC cells and its potential ...
Yang Yu, Fu-han Yang, Wen-tao Zhang, Ya-dong Guo, Lin Ye, Xu-dong Yao   +5 more
doaj   +1 more source